Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab

BACKGROUND: Management of disease-modifying therapies in Multiple Sclerosis (MS) during the COVID-19 pandemic is a controversial issue. Alemtuzumab is an immunosuppressive drug that induces lymphocytes depletion. In this study, we aimed to evaluate the frequency and severity of COVID-19 in a case se...

Descripción completa

Detalles Bibliográficos
Autores principales: Matías-Guiu, Jorge, Montero-Escribano, Paloma, Pytel, Vanesa, Porta-Etessam, Jesús, Matias-Guiu, Jordi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286822/
https://www.ncbi.nlm.nih.gov/pubmed/32554284
http://dx.doi.org/10.1016/j.msard.2020.102297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286822/
https://www.ncbi.nlm.nih.gov/pubmed/32554284
http://dx.doi.org/10.1016/j.msard.2020.102297

Ejemplares similares